Browsing by Author "Rabagliati, Ricardo"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item A prospective, multi-center study of Candida bloodstream infections in Chile(2019) Santolaya, Maria E.; Thompson, Luis; Tapia, Cecilia; Legarraga, Paulette; Cortés, Claudia; Rabello, Marcela; Valenzuela, Romina; Rojas, Pamela; Rabagliati, RicardoBackground Active surveillance is necessary for improving the management and outcome of patients with candidemia. The aim of this study was to describe epidemiologic and clinical features of candidemia in children and adults in tertiary level hospitals in Chile. Methods We conducted a prospective, multicenter, laboratory-based survey study of candidemia in 26 tertiary care hospitals in Chile, from January 2013 to October 2017. Results A total of 780 episodes of candidemia were included, with a median incidence of 0.47/1,000 admissions. Demographic, clinical and microbiological information of 384 cases of candidemia, from 18 hospitals (7,416 beds), was included in this report. One hundred and thirty-four episodes (35%) occurred in pediatric patients and 250 (65%) in adult population. Candida albicans (39%), Candida parapsilosis (30%) and Candida glabrata (10%) were the leading species, with a significant difference in the distribution of species between ages. The use of central venous catheter and antibiotics were the most frequent risk factors in all age groups (> 70%). Three hundred and fifteen strains were studied for antifungal susceptibility; 21 strains (6.6%) were resistant to fluconazole, itraconazole, voriconazole, anidulafungin or micafungin. The most commonly used antifungal therapies were fluconazole (39%) and echinocandins (36%). The overall 30-day survival was 74.2%, significantly higher in infants (82%) and children (86%) compared with neonates (72%), adults (71%) and elderly (70%). Conclusions Our prospective, multicenter surveillance study showed a low incidence of candidemia in Chile, with high 30-day survival, a large proportion of elderly patients, C. glabrata as the third most commonly identified strain, a 6.6% resistance to antifungal agents and a frequent use of echinocandins.Publication A prospective, multicenter study of invasive fungal disease caused by molds in children and adults in Chile(2025) Rabagliati, Ricardo; Benadof, Dona; Thompson, Luis; Garcia, Patricia; Gonzalez, Tamara; Vizcaya, Cecilia; Soto, Andres; Gutierrez, Catalina; Rodriguez, Lorena; Labraña, Yenis; Tapia, Cecilia; Zubieta, Marcela; Lasso, Martin; Gutierrez, Valentina; Contardo, Veronica; Castillo, Yocelyn; Ducasse, Karen; Calvo, Mario; Valenzuela, Romina; Santolaya, Maria; Chilean Invasive Mycosis NetworkBackground: Invasive mold diseases (IMDs) are a severe complication of immunocompromised subjects and an emerging problem among severely ill, apparently immunocompetent patients. The aim of this study was to describe the epidemiological and clinical features of IMDs in Chile. Methods: Prospective study of IMD cases in children and adults from 11 reference hospitals in Chile from May 2019 to May 2021. Results: One hundred seventy-six cases were included, 135 in adults and 41 in children, with an overall incidence of 0.4/1,000 admissions. The median age was 10.5 years in children and 56.6 years in adults, with male gender predominance in adults (61.5% versus 41.5%, p = 0.03). Immunosuppression was the most common condition in both children and adults. However, cancer, neutropenia, and hematopoietic cell transplantation were significantly more frequent in the pediatric group. In contrast, diabetes, viral pneumonia, chronic kidney disease, and chronic obstructive pulmonary disease were significantly more frequent among adult patients. Regarding the diagnostic category, 30.1% of cases were proven, 55.7% probable and 14.2% possible. Aspergillosis was the most frequent IMD diagnosed in 75.5% of cases, followed by fusariosis in children and mucormycosis in adults. Viral pneumonia was associated in 40.3% of cases, mainly COVID-19, with aspergillosis in 87.3%. No triazole resistance was observed in Aspergillus spp.. Antifungals were prescribed in 97.2% of the patients: voriconazole 61.4%, liposomal amphotericin 20.5%, combination antifungals 11.1%, and others 6.4%. Overall survival was 68.7%, 61.4%, and 51.7% at 30, 90 and 180 days, respectively. Discussion: This is the most extensive study of IMDs in Chile, evidencing an incidence of 0.4 per 1,000 admissions, with aspergillosis being the most frequent infection. Nearly 40% of cases were associated with respiratory viruses, accounting for the impact of COVID-19. Despite almost all patients starting antifungal therapy, the survival rate was poor. It is advisable to start a surveillance program of IMDs in Chile and verify the absence of azole resistance of Aspergillus spp.Publication Evidence-based clinical standard for the diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease(2025) Cortés, Jorge; Rodríguez, Diego; Valderrama, Martha; Rabagliati, Ricardo; Capone, Domenico; Álvarez, Carlos; Varón, Fabio; Nocua, Laura; Diaz, Cándida; Enciso, Leonardo; Cuervo, Sonia; Thompson, Luis; Corzo, Dora; Cuéllar, Luis; Vergara, Erika; Riera, Fernando; Cornejo, Patricia; Rojas, Rita; Gómez, Beatriz; Celis, Adriana; Sandoval, José; Sarmiento, Mauricio; Ochoa, Diana; Nucci, MarcioAspergillosis is a disease caused by the filamentous fungus Aspergillus spp. with a spectrum of clinical presentation that includes invasive and noninvasive forms. The invasive clinical presentation of aspergillosis most frequently affects people with compromised immune systems. In patients with oncohematologic pathology, invasive lung aspergillosis is a significant opportunistic mycosis, because it occurs frequently and has a major impact on morbidity, mortality, and high costs. The global problem of antimicrobial resistance, to which improper use of antifungals contributes, has put Aspergilus spp. in the spotlight, so it is important to generate guidelines for guidance in the proper use of antifungals in the management of invasive lung aspergillosis, to obtain better clinical outcomes and promote rational use of antifungals. This guideline contains recommendations for diagnosing and treating invasive lung aspergillosis in patients with oncohematologic disease, based on evidence and defined through a participatory process of expert consensus, for the Latin American context.